HIV care professionals are warning the public that threats to 340B drug discount savings “will compromise access to affordable care, treatment, and prevention services for underserved people with and at risk for HIV.”
The American Academy of HIV Medicine, the
…
The U.S. Health Resources and Services Administration (HRSA) has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.
HRSA told 340B Report in mid-September that in October it would resume
…
The Biden administration said yesterday it is delaying by six months the effective date of a Trump administration final rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing (VBP)
…
The federal fine for overcharging a 340B covered entity just went up from $5,883.00 to $5,953.00 per each instance of overcharging.
The U.S. Health and Human Services Department (HHS) Office of Inspector General (OIG) posted its annual inflation adjustments to
…
U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
In a Nov. 11 joint
…
Kaiser Health News (KHN), a nonprofit health care news organization whose stories are widely and freely republished and rebroadcast, released an in-depth article and news video today about the 340B program and the fight over 340B contract pharmacy.
According to
…
Drug manufacturer Eli Lilly late yesterday filed notice that it is appealing a federal district judge’s Oct. 29 ruling partially in Lilly’s favor and partially for the federal government on the legality of Lilly’s denials of 340B ceiling prices when
…
In a major organizational change, the U.S. Health Resources and Services Administration (HRSA) has redefined the job of Director of the Office of Pharmacy Affairs (OPA), the HRSA unit that runs the 340B program.
For the first time in 340B
…
The smoke is still clearing from three federal district judges’ recent decisions in drug manufacturers Lilly, Sanofi, Novo Nordisk, Novartis, and United Therapeutics’ 340B contract pharmacy lawsuits. In the rulings’ wake, we are keeping close tabs on what happens next
…*Sign up for news summaries and alerts from 340B Report